Cutaneous T-Cell Lymphoma Clinical Trials

University of Alabama at Birmingham
Birmingham Alabama 35233

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

University of Alabama - Birmingham
Birmingham Alabama 35233

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

UCLA Hematology Oncology
Los Angeles California 90095

A clinical research study of Brentuximab Vedotin and Methotrexate or Bexarotene for the treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma,, Mycosis Fungoides or Cutaneous T-Cell Lymphoma

UCLA Medical Center
Los Angeles California 90095

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

Stanford Cancer Center
Stanford California 94305

A clinical research study of Brentuximab Vedotin and Methotrexate or Bexarotene for the treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma,, Mycosis Fungoides or Cutaneous T-Cell Lymphoma

Stanford University
Stanford California 94305

Patients are needed to participate in a clinical research study evaluating SHP-141 and placebo fo SHP-141 for the treatment of Lymphoma, T-Cell, Cutaneous

Stanford Medical Center
Stanford California 94305

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

Yale University School of Medicine - Yale Cancer Center
New Haven Connecticut 06520

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

Florida Academic Dermatology Centers
Miami Florida 33136

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

Moffitt Cancer Center and Research Institute
Tampa Florida 33612

A clinical research study of Brentuximab Vedotin and Methotrexate or Bexarotene for the treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma,, Mycosis Fungoides or Cutaneous T-Cell Lymphoma

H. Lee Moffitt Cancer Center
Tampa Florida 33612

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

Emory University
Atlanta Georgia 30322

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

The Winship Cancer Institute (Emory University)
Atlanta Georgia 30322

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

Northwestern Memorial Hospital
Chicago Illinois 60611

A clinical research study of Brentuximab Vedotin and Methotrexate or Bexarotene for the treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma,, Mycosis Fungoides or Cutaneous T-Cell Lymphoma

Northwestern University Dept of Dermatology
Chicago Illinois 60611

Patients are needed to participate in a clinical research study evaluating SHP-141 and placebo fo SHP-141 for the treatment of Lymphoma, T-Cell, Cutaneous

Rush University
Chicago Illinois 60612

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

Northwestern University
Chicago Illinois 60611

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

Tulane
New Orleans Louisiana 70112

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

Tulane University Medical Center
New Orleans Louisiana 70112

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

Dana-Farber Cancer Institute
Boston Massachusetts 02215-5450

A clinical research study of Brentuximab Vedotin and Methotrexate or Bexarotene for the treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma,, Mycosis Fungoides or Cutaneous T-Cell Lymphoma

Boston University Medical Center
Boston Massachusetts 02118

A clinical research study of Brentuximab Vedotin and Methotrexate or Bexarotene for the treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma,, Mycosis Fungoides or Cutaneous T-Cell Lymphoma

Boston Medical Center
Boston Massachusetts 02118

Patients are needed to participate in a clinical research study evaluating Everolimus for the treatment of Cutaneous T-Cell Lymphoma

University of Michigan
Ann Arbor Michigan 48109

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

University of Minnesota Medical School
Minneapolis Minnesota 55455

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

Washington University
St. Louis Missouri 63110

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

Washington University School of Medicine
St. Louis Missouri 63110

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

Dartmouth Hitchcock Medical Center
Lebanon New Hampshire 03756

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

John Theurer Cancer Center (Hackensack University Medical Center)
Hackensack New Jersey 07601

A clinical research study of Brentuximab Vedotin and Methotrexate or Bexarotene for the treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma,, Mycosis Fungoides or Cutaneous T-Cell Lymphoma

Memorial Sloan-Kettering Cancer Center
New York New York 10021

A clinical research study of Brentuximab Vedotin and Methotrexate or Bexarotene for the treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma,, Mycosis Fungoides or Cutaneous T-Cell Lymphoma

Columbia Presbyterian
New York New York 10037

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

University of Rochester
Rochester New York 14642

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

University of Rochester School of Medicine
Rochester New York 14642

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

Duke University
Durham North Carolina 27710

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

Wake Forest University Health
Winston-Salem North Carolina 27157

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

Cleveland Clinic
Cleveland Ohio 44195

Patients are needed to participate in a clinical research study evaluating SHP-141 and placebo fo SHP-141 for the treatment of Lymphoma, T-Cell, Cutaneous

University Hospitals-Case Medical Center
Cleveland Ohio 44106

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

University Hospitals Case Medical Center
Cleveland Ohio 44106

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

University of Pennsylvania
Philadelphia Pennsylvania 19104

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

University of Pittsburgh
Pittsburgh Pennsylvania 15213

A clinical research study of Brentuximab Vedotin and Methotrexate or Bexarotene for the treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma,, Mycosis Fungoides or Cutaneous T-Cell Lymphoma

University of Pittsburgh
Pittsburgh Pennsylvania 15213

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

University of Pittsburgh School of Medicine
Pittsburgh Pennsylvania 15208

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

Vanderbilt
Nashville Tennessee 37206

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

Vanderbilt University Medical Center
Nashville Tennessee 37232

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

University of Texas Southwestern Medical Center
Dallas Texas 75390

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

MD Anderson Cancer Center
Houston Texas 77030

A clinical research study of Brentuximab Vedotin and Methotrexate or Bexarotene for the treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma,, Mycosis Fungoides or Cutaneous T-Cell Lymphoma

MD Anderson Cancer Center
Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating SHP-141 and placebo fo SHP-141 for the treatment of Lymphoma, T-Cell, Cutaneous

MD Anderson Cancer Center
Houston Texas 77030

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

M.D.Anderson Cancer Center
Houston Texas 77030

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma

Huntsman Cancer Institute At the University of Utah
Salt Lake City Utah 84112

Patients are needed to participate in a clinical research study of bexarotene to evaluate Refractory Cutaneous T-cell Lymphoma

Medical College of Wisconsin
Milwaukee Wisconsin 53266

Patients are needed to participate in a clinical research study of KW-0761 and Vorinostat to evaluate Cutaneous T-Cell Lymphoma